CA2322161A1 - Inhibiteurs d'enzymes phospholipases - Google Patents

Inhibiteurs d'enzymes phospholipases Download PDF

Info

Publication number
CA2322161A1
CA2322161A1 CA002322161A CA2322161A CA2322161A1 CA 2322161 A1 CA2322161 A1 CA 2322161A1 CA 002322161 A CA002322161 A CA 002322161A CA 2322161 A CA2322161 A CA 2322161A CA 2322161 A1 CA2322161 A1 CA 2322161A1
Authority
CA
Canada
Prior art keywords
alkyl
methyl
phenyl
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002322161A
Other languages
English (en)
Inventor
Yibin Xiang
Jean E. Bemis
Neelu Kaila
Jasbir S. Seehra
Frank Lovering
John C. Mckew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2322161A1 publication Critical patent/CA2322161A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés qui inhibent l'activité d'enzymes phospholipases, en particulier la phospholipase A¿2? cytosolique. On décrit des compositions pharmaceutiques contenant lesdits composés et des méthodes de traitement mettant en oeuvre lesdites compositions.
CA002322161A 1998-02-25 1999-02-24 Inhibiteurs d'enzymes phospholipases Abandoned CA2322161A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3006298A 1998-02-25 1998-02-25
US09/030,062 1998-02-25
PCT/US1999/003899 WO1999043651A2 (fr) 1998-02-25 1999-02-24 Inhibiteurs d'enzymes phospholipases

Publications (1)

Publication Number Publication Date
CA2322161A1 true CA2322161A1 (fr) 1999-09-02

Family

ID=21852314

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002322161A Abandoned CA2322161A1 (fr) 1998-02-25 1999-02-24 Inhibiteurs d'enzymes phospholipases

Country Status (19)

Country Link
EP (1) EP1056719A2 (fr)
JP (1) JP2002504539A (fr)
KR (1) KR20010041343A (fr)
CN (1) CN1299347A (fr)
AU (1) AU2782699A (fr)
BG (1) BG104780A (fr)
BR (1) BR9908280A (fr)
CA (1) CA2322161A1 (fr)
EA (1) EA200000868A1 (fr)
EE (1) EE200000486A (fr)
HR (1) HRP20000552A2 (fr)
HU (1) HUP0100757A3 (fr)
ID (1) ID27280A (fr)
IL (1) IL137718A0 (fr)
NO (1) NO20004220L (fr)
PL (1) PL342995A1 (fr)
SK (1) SK12742000A3 (fr)
TR (1) TR200002446T2 (fr)
WO (1) WO1999043651A2 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1177186B1 (fr) * 1999-05-05 2004-03-31 Aventis Pharma Limited Urees en tant que modulateurs de l'adhesion cellulaire
AU2001277056B2 (en) 2000-07-25 2005-09-29 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
JP4615826B2 (ja) 2001-01-29 2011-01-19 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換インドールおよびインテグリンアンタゴニストとしてのそれらの使用
US6916850B2 (en) 2001-05-03 2005-07-12 Galileo Pharmaceuticals, Inc. Pyruvate derivatives
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
WO2003000253A1 (fr) 2001-06-20 2003-01-03 Wyeth Derives d'acide indole substitue utilises en tant qu'inhibiteurs de l'inhibiteur-1 (pai-1) de l'activateur plasminogene
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7291639B2 (en) 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
EP1410822A4 (fr) * 2001-06-25 2007-06-20 Nippon Soda Co Composes oxa(thia)zolidine, processus de preparation de ceux-ci et agents anti-inflammatoires.
US6635771B2 (en) 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
KR100973665B1 (ko) * 2001-12-03 2010-08-04 와이어쓰 엘엘씨 세포질 포스포리파제 ａ2의 억제제
EP1892239B1 (fr) * 2001-12-03 2013-02-20 Wyeth LLC Inhibitieurs de la phospholipase A2 cytosolique
US6797708B2 (en) * 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US7101875B2 (en) 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
US6984735B2 (en) 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
WO2004019869A2 (fr) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles presentant un effet antidiabetique
AU2003265681A1 (en) 2002-08-29 2004-03-19 Merck And Co., Inc. Indoles having anti-diabetic activity
KR20050072812A (ko) 2002-11-07 2005-07-12 악조 노벨 엔.브이. 안드로겐-수용체와 관련된 질병의 치료에 효과적인 인돌
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
ES2325071T3 (es) 2002-12-10 2009-08-25 Wyeth Derivados del acido indol-oxo-acetilaminoacetico sustituido como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1).
DE60324183D1 (en) 2002-12-10 2008-11-27 Wyeth Corp Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
DE60306547T2 (de) 2002-12-10 2007-06-28 Wyeth Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen-aktivator
JP2006514637A (ja) 2002-12-10 2006-05-11 ワイス プラスミノーゲン活性化因子の阻害因子−１（ｐａｉ−１）の阻害剤としての置換３−カルボニル−１ｈ−インドール−１−イル酢酸誘導体
TW200510305A (en) * 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
CN101006053A (zh) 2004-06-18 2007-07-25 比奥里波克斯公司 用于治疗炎症的吲哚
CA2577857A1 (fr) 2004-08-23 2006-03-02 Wyeth Acides d'oxazolo-naphthyl utilises en tant modulateurs de l'inhibiteur de type-1 (pai-1) de l'activateur de plasminogene utiles dans le traitement de la thrombose et des maladies cardio-vasculaires
BRPI0517369A (pt) * 2004-10-27 2008-10-07 Hoffmann La Roche compostos, processo para a sua manufatura, composições que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
BRPI0519774A2 (pt) * 2005-01-19 2009-02-10 Biolipox Ab composto ou um sal farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, mÉtodo de tratamento de uma doenÇa em que inibiÇço da atividade de um membro da famÍlia mapeg É desejada e/ou necessÁria, produto combinado, e, processo para a preparaÇço de um composto
WO2007024294A2 (fr) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certains urees substitues, modulateurs de l'activite des kinases
GT200600228A (es) * 2005-05-27 2006-12-26 Inhibidores de la fosfolipasa a2 citosolica
WO2007022321A2 (fr) 2005-08-17 2007-02-22 Wyeth Indoles substitues et procedes d'utilisation de ceux-ci
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8168673B2 (en) 2008-01-22 2012-05-01 Oxagen Limited Compounds having CRTH2 antagonist activity
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
PT2448938E (pt) 2009-06-29 2014-07-31 Incyte Corp Pirimidinonas como inibidoras de pi3k
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
JP5816678B2 (ja) 2010-04-14 2015-11-18 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ＰＩ３Ｋδ阻害剤としての縮合誘導体
WO2011163195A1 (fr) 2010-06-21 2011-12-29 Incyte Corporation Dérivés condensés de pyrrole en tant qu'inhibiteurs de pi3k
EP2655374B1 (fr) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(phényl substitué)éthyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k
WO2012125629A1 (fr) 2011-03-14 2012-09-20 Incyte Corporation Dérivés diamino-pyrimidines et diamino-pyridines substituées en tant qu'inhibiteurs de pi3k
WO2012135009A1 (fr) 2011-03-25 2012-10-04 Incyte Corporation Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k
JP6067709B2 (ja) 2011-09-02 2017-01-25 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
HUE036238T2 (hu) 2012-07-17 2018-06-28 Glaxosmithkline Ip No 2 Ltd Szelektív androgén receptor modulátorokként ható indolkarbonitril vegyületek
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
PT3831833T (pt) 2015-02-27 2023-02-06 Incyte Corp Processos para a preparação de um inibidor pi3k
WO2016183060A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Procédé de synthèse d'un inhibiteur de phospho-inositide 3-kinases
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
EP4364798A2 (fr) 2018-10-05 2024-05-08 Annapurna Bio Inc. Composés et compositions pour le traitement d'états associés à l'activité du récepteur apj

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE314373B (fr) * 1966-04-12 1969-09-08 Sumitomo Chemical Co
FR1492929A (fr) * 1966-05-11 1967-08-25 Roussel Uclaf Nouveaux 1-(omega-carboxyalcoyl) indoles substitués et procédé de préparation
US3505354A (en) * 1967-05-18 1970-04-07 Geigy Chem Corp 2-methyl-3-p-halobenzoylindole-n-aliphatic acids
DE1816335A1 (de) * 1968-12-21 1970-07-09 Thiemann Gmbh Chem Pharm Fabri Verfahren zur Herstellung von [2-Methyl-5-alkoxy-3-acyl-indol-1]-essigsaeuren und deren Estern
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
CA1337202C (fr) * 1988-04-13 1995-10-03 Victor Giulio Matassa Amides cycliques qui sont des antagonistes des leucotrienes
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5290798A (en) * 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
CA2135605A1 (fr) * 1992-05-13 1993-11-25 Lawrence E. Fisher Indoles et azaindoles substitues agissant comme antagonistes de l'angiotensine ii
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
DE4338770A1 (de) * 1993-11-12 1995-05-18 Matthias Dr Lehr Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
JP2000515529A (ja) * 1996-08-01 2000-11-21 メルクル・ゲーエムベーハー 細胞質ホスホリパーゼａ▲下２▼の阻害剤としてのアシルピロリドンジカルボン酸およびアシルインドールジカルボン酸ならびにその誘導体
WO1998008818A1 (fr) * 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibiteurs des enzymes phospholipases

Also Published As

Publication number Publication date
NO20004220D0 (no) 2000-08-23
WO1999043651A2 (fr) 1999-09-02
JP2002504539A (ja) 2002-02-12
BR9908280A (pt) 2000-10-31
WO1999043651A3 (fr) 1999-12-16
PL342995A1 (en) 2001-07-16
TR200002446T2 (tr) 2000-12-21
SK12742000A3 (sk) 2001-05-10
HUP0100757A3 (en) 2001-11-28
IL137718A0 (en) 2001-10-31
ID27280A (id) 2001-03-22
EA200000868A1 (ru) 2001-04-23
HUP0100757A1 (hu) 2001-08-28
NO20004220L (no) 2000-10-05
CN1299347A (zh) 2001-06-13
HRP20000552A2 (en) 2001-04-30
EP1056719A2 (fr) 2000-12-06
EE200000486A (et) 2002-02-15
AU2782699A (en) 1999-09-15
KR20010041343A (ko) 2001-05-15
BG104780A (en) 2001-10-31

Similar Documents

Publication Publication Date Title
CA2322161A1 (fr) Inhibiteurs d'enzymes phospholipases
US6828344B1 (en) Inhibitors of phospholipase enzymes
US6916841B2 (en) Inhibitors of phospholipase enzymes
AU765427B2 (en) Inhibitors of phospholipase enzymes
CA2322163A1 (fr) Inhibiteurs de la phospholipase a2
US5459150A (en) Indole derivatives which inhibit leukotriene biosynthesis
US6630496B1 (en) Inhibitors of phospholipase enzymes
KR100330816B1 (ko) H-인돌-3-아세트산하이드라이드spla2억제제
US8912186B2 (en) Allosteric protein kinase modulators
JPH05140102A (ja) 尿素誘導体およびその製造法
ES2428539T9 (es) Nuevos inhibidores de histona deacetilasas
CA2330555A1 (fr) Derives de naphto[2,3-b]heteroar-4-yle
JPH01110682A (ja) 抗アレルギー性活性を有する新規ベンゾチオフエン
JP2006516982A (ja) ホスホリパーゼａ２阻害剤としての新規ヘテロアリール置換アセトン誘導体
EP2001846A1 (fr) Dérivés d'indole en tant qu'inhibiteurs de l'adénylate cyclase soluble
MXPA00008295A (en) Inhibitors of phospholipase enzymes
CZ20003113A3 (cs) Inhibitory fosfolipázy
MXPA00008292A (en) Inhibitors of phospholipase enzymes
CZ20003117A3 (cs) Inhibitory fosfolipázy
MXPA00008294A (en) Inhibitors of phospholipase a2

Legal Events

Date Code Title Description
FZDE Discontinued